Helping your patients to learn to self-infuse will help them to better manage their bleeding disorder. Please take a few moments to watch the video, and pretty soon, your patients will be infusing quickly and comfortably-and experiencing the freedom and independence that self-infusion brings. View the video demonstration below on the 6 simple steps to self-infuse Humate-P® using the Mix2Vial™ device.
If you don't have high-speed Internet access. . .
For users without high-speed access, the video may take several minutes to download.
Contact us at 1-800-504-5434 if you need more information about self-infusing Humate-P® using the Mix2Vial™ Needle-free Transfer Device.
Important Safety Information
Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P® is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.
Humate-P® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or
von Willebrand factor preparations, or to any of its components.
Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.
Humate-P® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Although few adverse reactions have been reported in patients receiving Humate-P®, the most commonly reported are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.
Please see accompanying full prescribing information for Humate-P®.
The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.
|||
||
© CSL Behring 2009. The product information presented on this site is intended for US residents only.
|
